To accelerate clinical trial activation and execution, enhance research quality, and strengthen international competitiveness, Taiwan's Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) has officially signed a Memorandum of Understanding (MoU) with AbbVie, a globally renowned biopharmaceutical company.
Through the implementation of the “SC Helper Programme,” this collaboration further deepens the strategic partnership between the two parties and sets a new benchmark for efficient clinical research collaboration.
A key highlight of this partnership is KMUH’s achievement in being the first among global research centers to enroll a patient in a clinical trial for metastatic colorectal cancer.
Backed by comprehensive research capabilities and extensive clinical experience, the Kaohsiung Medical University healthcare system has long focused on the clinical phases of new drug development. It has collaborated with AbbVie in 21 international clinical trials across major disease areas such as immunology, hematology, and solid tumours.
Clinical trials serve as a vital bridge between innovation and clinical practice. The signing of this MoU marks a new chapter in the collaboration between KMUH and AbbVie. In addition to enhancing trial quality through resource integration, the partnership also brings comprehensive improvements in key areas such as contract review streamlining, startup process acceleration, and patient recruitment efficiency.
KMUH is actively aligning with the Ministry of Health and Welfare’s “New Model of Excellence in Clinical Trials Programme,” focusing on quality enhancement, the advancement of decentralised clinical trials (DCT), and the establishment of mechanisms for international harmonisation.
